Primary prophylaxis with G-CSF is not indicated in patients with solid tumors treated with chemotherapy with low or intermediate risk (
The purpose of this prospective, multicenter study was to develop and validate a risk model to predict the occurrence of CRNE in patients with solid tumors receiving chemotherapy with low or intermediate risk of FN (
The incidence of CRNE was 19.3%. Female gender, metastatic stage, treatment with platinum or anthracyclines-based chemotherapy, and low baseline hemoglobin or neutrophil count were independent predictive factors for CRNE. The accuracy of the model was 82.8% with sensitivity of 24.2%, specificity of 97.7%, positive and negative predictive values (PV) 71.4% and 84.3% respectively. The ROC analysis of training datasets yielded an area under the curve (AUC) of 0.791 (95%CI: 0.729–0.852). A ROC curve plotted for the validation sample yielded similar AUC (0.856; 95%CI: 0.769-0.944), accuracy (85%), Sensitivity (47,4%), Specificity (96.3%), PV+ (75%) and PV- (86.6%).
This model can identify patients at high risk of CRNE before the chemotherapy with low or intermediate risk of FN is started, allowing clinicians an opportunity to plan appropriate and timely neutropenia management.
Clinical trial identification
The number of the trial protocol: AFI-QUI-2011-01
Legal entity responsible for the study
AFIDIO: Asociación para el Fomento de la Investigación y Desarrollo Integral de la Oncología
All authors have declared no conflicts of interest.